Systemic Inflammatory Response Evaluation With the Use of Inhaled Anesthetic Sevoflurane During CPB

Instituto Dante Pazzanese de Cardiologia

Status: Completed

Conditions: Inflammatory Response

Treatments: Drug: Sevoflurane

Study type: Observational

Funder types: Other

Identifiers

NCT02672345

4617

Details and patient eligibility

About

Cardiac surgery has evolved considerably after the advent of cardiopulmonary bypass (CPB), a feature that allowed more precision and tranquility to the heart surgeon. But their influence on exacerbation of inflammatory response can unbalance the whole homeostasis so happens surgical trauma. The attenuation of the systemic inflammatory response in major surgeries like cardiac surgery for aortic aneurysm appears to represent an important advance in reducing morbidity and mortality of these patients. Some studies suggest that inhaled anesthetics such as sevoflurane appear to play an important role in this control, but the mechanism by which this happens is still unclear. This study has the primary purpose of analyzing from a clinical study sevoflurane inhalation anesthetic can change the inflammatory response induced by CPB, significantly reducing the release of inflammatory markers, especially elastase PMN.

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age over 18 years
• Cardiac Surgery elective of coronary artery bypass graft with cardiopulmonary bypass (CPB)
• The informed consent signature savvy

Exclusion criteria

• Use of steroids or anti-inflammatory drugs routine
• Presence of asthma, COPD, autoimmune diseases
• Participation in other clinical studies
• Presence of decompensated heart failures, liver or kidney
• Combined elective surgery (ex .: aneurysm correction + CABG)
• Acute myocardial infarction in the last 30 days
• Unstable angina
• And obesity (BMI> 50kg / m2)

Trial design

100 participants in 2 patient groups

Sevoflurane Group

Description:

Group of patients receiving sevorane during extracorporeal circulation period.

Treatment:

Drug: Sevoflurane

Not Sevoflurane Group

Description:

Group of patients who did not receive the sevorane during extracorporeal circulation period.